TMCnet News
OTCPicks.com: OTCPicks.com Stocks to Watch for Tuesday, December 16th JNIP, WGAT, IVVI, MRNADec 16, 2008 (M2 PRESSWIRE via COMTEX) -- Our Stocks to Watch tomorrow include Juniper Group Inc. (OTCBB: JNIP), WorldGate Communications Inc. (OTCBB: WGAT), Ivivi Technologies Inc. (Nasdaq: IVVI) and MDRNA Inc. (Nasdaq: MRNA). Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts. JUNIPER GROUP INCORPORATED (OTCBB: JNIP) "Up 333.33% on Monday" Detailed Quote: http://www.otcpicks.com/quotes/JNIP.php Juniper Group, Inc., through its subsidiaries, provides broadband installation and wireless infrastructure services in the United States. Its services include deployment of wireless/tower systems; maintenance and upgrading of wireless telecommunications sites; and site surveys, co-location facilitation, tower construction and antenna installation to tower system integration, and hardware and software installations. The company offers its services primarily to telecommunication companies. Juniper Group also engages in the acquisition, exploitation, and distribution of rights to films for various media, such as DVD, satellite, home video, pay-per view, pay television, television, and independent syndicated television stations. The company was founded in 1987 and is headquartered in Boca Raton, Florida. JNIP News: December 15 - Juniper Announces That It Has Secured Financing from Investment Banking Firm and Accounts Receivable Firm Juniper Group, Inc. (OTCBB: JNIP) announced that it has secured ongoing funding from its Investment Banking firm and is in final negotiations with Riviera Financing Inc., an accounts receivable financing company for its wholly-owned Infrastructure Service subsidiary. This will enable Juniper to implement the contracts that it has shored up recently with two of the nation's largest telecommunication companies in performing build outs, lines and antennas, and the upgrading of infrastructure and power sources in the Indianapolis market. Further, the implementation of new jobs and the utilization of Riviera Financing Inc would enable immediate cash flow for the Company. This immediate cash flow assures that its Infrastructure Services subsidiary can continue to take on more opportunities and grow in the telecom infrastructure marketplace. With technology growth burgeoning at unprecedented rates, this financing would allow the Company to be competitive in solicitation of new business and continue to service its clients in the manner they have come to expect. This comes on the heels of the Infrastructure Services subsidiary Chapter 11 Reorganization filing. Vlado P. Hreljanovic, President of the Company stated, "This funding allows the Company to move forward in a very positive way while enabling us to set concrete goals for our reorganization. We are very encouraged that we can maintain or improve our employment levels during this very difficult time in our nation's economy." WORLDGATE COMMUNICATIONS INCORPORATED (OTCBB: WGAT) "Up 216.90% on Monday" Detailed Quote: http://www.otcpicks.com/quotes/WGAT.php WorldGate Communications, Inc. engages in the development and sale of video phone products and technology in the United States and internationally. It offers Ojo video phones for in-home and business, personal video communication. The company's video phones are designed for use on the high speed data (HSD) network infrastructure primarily for video calls, ordinary voice only calls, and voice over Internet protocol calls. WorldGate Communications markets its products to HSD network operators, as well as to consumers through consumer electronics distribution channels. The company was founded in 1995 and is headquartered in Trevose, Pennsylvania. WGAT News: December 15 - Unit of ACN Buys Stake in WorldGate The Charlotte Business Journal reports that WGI Investor, a private investment fund partially owned by ACN Inc., has agreed to buy a controlling interest in WorldGate Communications Inc. (OTCBB: WGAT). For more details, visit: http://charlotte.bizjournals.com/charlotte/stories/2008/12/15/daily7.html?ana=yf cpc IVIVI TECHNOLOGIES INCORPORATED (NASDAQ: IVVI) "Up 230.77% on Monday" Detailed Quote: http://www.otcpicks.com/quotes/IVVI.php Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform, with a primary focus on developing treatments for cardiovascular disease. Ivivi's research and development activities are focused specifically on targeted pulsed electromagnetic field, or tPEMF(tm), technology, which, by creating a therapeutic electrical current in injured soft tissue, is believed to modulate biochemical and physiological healing processes to help reduce related pain and inflammation. The Company's most recent clinical studies have shown reductions in anginal pain and increases in blood flow to the heart in certain cardiac patients; however, additional studies will be focused in this area. The Company also expects to seek strategic partners to pursue other markets, such as osteoarthritis, neurology and other inflammatory-related conditions if FDA marketing approvals or clearances can be achieved in these areas. IVVI News: October 16 - Ivivi Technologies Receives FDA 510(k) Clearance for its Latest Generation SofPulse, Roma3 and Torino II Electrotherapy Systems Ivivi Technologies, Inc. (Nasdaq: IVVI), a leader in non-invasive, electrotherapy systems, announced that it received U.S. Food and Drug Administration (FDA) 510(k) Clearance for the Company's currently marketed targeted pulsed electromagnetic field (tPEMF) therapeutic products. The 510(k) Substantial Equivalence Determination specifically covers the Company's SofPulse Models 912-M10, Roma(3) and Torino II products which are indicated for the palliative treatment of post operative pain and edema in superficial soft tissue. "We are extremely pleased the FDA has thoroughly reviewed the substantial amount of data covering our family of tPEMF(tm) products, which included biophysical dosimetry studies and randomized, placebo-controlled animal and human clinical trials submitted in support of this 510(k)," commented Steven Gluckstern, Chairman, President and Chief Executive Officer. "We believe this clearance is a particularly significant milestone for the Company. Ivivi is now further enabled to expand the distribution of our technology into the important markets of post operative pain and edema and for pain and swelling in chronic wounds. This latest generation of Ivivi signals evolved as a result of our significant advances in understanding the mechanism of action of tPEMF(tm). This knowledge and the ability to freely market the SofPulse family of products for its labeled indications are important steps in helping Ivivi realize the full potential of this broad-based, effective electrotherapeutic treatment modality." ABOUT TARGETED PEMF Targeted Pulsed Electromagnetic Field therapy delivers signals which reduce pain and edema associated with inflammation. These signals have demonstrated reductions in patient morbidity by accelerating reduction of acute post operative pain and edema and have demonstrated lower pharmacological analgesic use in a recently published randomized controlled trial. Ivivi's technology is drug-free, easy to apply and has an excellent safety profile. The latest generation signals, which are the subject of the 510(k) clearance, evolved as a result of our significant advances in understanding the mechanism of action of tPEMF(tm). The resulting SofPulse devices are also more portable, disposable and more economical than existing predicate devices, all with significantly lowered electromagnetic interference. This opens the way for on-label tPEMF(tm) use in conditions for which electromagnetic field therapy has not readily been utilized. MDRNA INCORPORATED (NASDAQ: MRNA) "Up 167.53% on Monday" Detailed Quote: http://www.otcpicks.com/quotes/MRNA.php MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in key therapeutic areas including oncology, metabolic disorders and inflammation. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. MRNA News: December 15 - MDRNA, Inc. Announces Tentative FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis MDRNA, Inc. (Nasdaq: MRNA) announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval of MDRNA's Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Full FDA approval would follow the completion of Apotex's 180-day exclusivity period, or June 2009. MDRNA's generic calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin were approximately $147 million in 2007. On December 23, 2003, FDA accepted for filing MDRNA's 505(j) paragraph 4 ANDA for the product. In October 2004, MDRNA and Par Pharmaceutical Companies, Inc. entered into an exclusive license and supply agreement for U.S. distribution and marketing of the product. Under terms of the agreement, MDRNA is responsible for obtaining regulatory approval and manufacturing, and will receive product transfer payments for manufactured product and profit sharing following commercialization. "We are pleased that our generic calcitonin-salmon nasal spray has received tentative FDA approval and we look forward to full FDA approval in mid 2009," stated J. Michael French, President and CEO of MDRNA. "Although we are now a company solely focused in the research and development of RNAi-based therapeutics, we are pleased to see the successful culmination of years of hard work on the part of many current and former members of the MDRNA/Nastech team. I want to personally thank them all for their efforts in bringing this product forward. We are assessing our short- and long-term options to understand how this tentative approval can be leveraged toward the continued advancement of our RNAi drug discovery engine." ABOUT CALCITONIN MDRNA's calcitonin-salmon nasal spray is a generic version of Miacalcin , an FDA approved calcitonin-salmon nasal spray marketed by Novartis for the treatment of osteoporosis. Calcitonin is a natural peptide hormone produced by the thyroid gland that acts primarily on bone. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency is greater due to a longer duration of action. Novartis' Miacalcin has been shown to increase spinal bone mass in post-menopausal women with established osteoporosis. ABOUT OTCPICKS.COM OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [email protected]. Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever. Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. Third Party Web Sites and Information: OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: [email protected] M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |